REGENERON PHARMACEUTICALS (REGN) Stock Fundamental Analysis

NASDAQ:REGN • US75886F1075

792.16 USD
-1.37 (-0.17%)
At close: Feb 18, 2026
793 USD
+0.84 (+0.11%)
After Hours: 2/18/2026, 6:59:08 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

REGN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making REGN a very profitable company, without any liquidiy or solvency issues. REGN has a decent growth rate and is not valued too expensively. This makes REGN very considerable for quality investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year REGN was profitable.
  • REGN had a positive operating cash flow in the past year.
  • In the past 5 years REGN has always been profitable.
  • In the past 5 years REGN always reported a positive cash flow from operatings.
REGN Yearly Net Income VS EBIT VS OCF VS FCFREGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

1.2 Ratios

  • The Return On Assets of REGN (11.11%) is better than 93.86% of its industry peers.
  • Looking at the Return On Equity, with a value of 14.41%, REGN belongs to the top of the industry, outperforming 94.24% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 9.60%, REGN belongs to the top of the industry, outperforming 94.24% of the companies in the same industry.
  • REGN had an Average Return On Invested Capital over the past 3 years of 11.30%. This is significantly below the industry average of 18.69%.
Industry RankSector Rank
ROA 11.11%
ROE 14.41%
ROIC 9.6%
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)11.3%
ROIC(5y)18.08%
REGN Yearly ROA, ROE, ROICREGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • The Profit Margin of REGN (31.41%) is better than 96.16% of its industry peers.
  • In the last couple of years the Profit Margin of REGN has declined.
  • REGN's Operating Margin of 27.02% is amongst the best of the industry. REGN outperforms 95.97% of its industry peers.
  • REGN's Operating Margin has declined in the last couple of years.
  • The Gross Margin of REGN (86.56%) is better than 89.06% of its industry peers.
  • In the last couple of years the Gross Margin of REGN has remained more or less at the same level.
Industry RankSector Rank
OM 27.02%
PM (TTM) 31.41%
GM 86.56%
OM growth 3Y-14.45%
OM growth 5Y-8.44%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.04%
GM growth 5Y-0.06%
REGN Yearly Profit, Operating, Gross MarginsREGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so REGN is still creating some value.
  • REGN has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, REGN has less shares outstanding
  • REGN has a better debt/assets ratio than last year.
REGN Yearly Shares OutstandingREGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
REGN Yearly Total Debt VS Total AssetsREGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • REGN has an Altman-Z score of 7.72. This indicates that REGN is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of REGN (7.72) is better than 78.89% of its industry peers.
  • The Debt to FCF ratio of REGN is 0.72, which is an excellent value as it means it would take REGN, only 0.72 years of fcf income to pay off all of its debts.
  • REGN's Debt to FCF ratio of 0.72 is amongst the best of the industry. REGN outperforms 94.43% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that REGN is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.09, REGN is not doing good in the industry: 61.04% of the companies in the same industry are doing better.
  • Although REGN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.72
Altman-Z 7.72
ROIC/WACC1.13
WACC8.46%
REGN Yearly LT Debt VS Equity VS FCFREGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.3 Liquidity

  • REGN has a Current Ratio of 4.13. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
  • REGN has a Current ratio of 4.13. This is comparable to the rest of the industry: REGN outperforms 49.33% of its industry peers.
  • A Quick Ratio of 3.56 indicates that REGN has no problem at all paying its short term obligations.
  • REGN has a Quick ratio of 3.56. This is comparable to the rest of the industry: REGN outperforms 44.72% of its industry peers.
Industry RankSector Rank
Current Ratio 4.13
Quick Ratio 3.56
REGN Yearly Current Assets VS Current LiabilitesREGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.76%.
  • The Earnings Per Share has been growing slightly by 6.99% on average over the past years.
  • Looking at the last year, REGN shows a small growth in Revenue. The Revenue has grown by 0.99% in the last year.
  • REGN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.04% yearly.
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%

3.2 Future

  • REGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.00% yearly.
  • The Revenue is expected to grow by 8.09% on average over the next years. This is quite good.
EPS Next Y4.68%
EPS Next 2Y11.02%
EPS Next 3Y11.23%
EPS Next 5Y11%
Revenue Next Year9.08%
Revenue Next 2Y9.41%
Revenue Next 3Y8.95%
Revenue Next 5Y8.09%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
REGN Yearly Revenue VS EstimatesREGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
REGN Yearly EPS VS EstimatesREGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20 40 60 80

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 17.85, REGN is valued on the expensive side.
  • 95.59% of the companies in the same industry are more expensive than REGN, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 27.27, REGN is valued a bit cheaper.
  • The Price/Forward Earnings ratio is 17.05, which indicates a rather expensive current valuation of REGN.
  • Based on the Price/Forward Earnings ratio, REGN is valued cheaply inside the industry as 94.82% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of REGN to the average of the S&P500 Index (28.16), we can say REGN is valued slightly cheaper.
Industry RankSector Rank
PE 17.85
Fwd PE 17.05
REGN Price Earnings VS Forward Price EarningsREGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 95.59% of the companies in the same industry are more expensive than REGN, based on the Enterprise Value to EBITDA ratio.
  • 95.01% of the companies in the same industry are more expensive than REGN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 22.24
EV/EBITDA 12.85
REGN Per share dataREGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200 250

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates REGN does not grow enough to justify the current Price/Earnings ratio.
  • REGN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.82
PEG (5Y)2.55
EPS Next 2Y11.02%
EPS Next 3Y11.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. Dividend

5.1 Amount

  • REGN has a yearly dividend return of 0.48%, which is pretty low.
  • REGN's Dividend Yield is rather good when compared to the industry average which is at 1.17. REGN pays more dividend than 98.27% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.84, REGN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.48%

5.2 History

  • REGN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
REGN Yearly Dividends per shareREGN Yearly Dividends per shareYearly Dividends per share 2025 2026 1 2 3

5.3 Sustainability

  • 8.22% of the earnings are spent on dividend by REGN. This is a low number and sustainable payout ratio.
DP8.22%
EPS Next 2Y11.02%
EPS Next 3Y11.23%
REGN Yearly Income VS Free CF VS DividendREGN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
REGN Dividend Payout.REGN Dividend Payout, showing the Payout Ratio.REGN Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

REGENERON PHARMACEUTICALS

NASDAQ:REGN (2/18/2026, 6:59:08 PM)

After market: 793 +0.84 (+0.11%)

792.16

-1.37 (-0.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-30
Earnings (Next)04-27
Inst Owners90.13%
Inst Owner Change-1.05%
Ins Owners1.95%
Ins Owner Change3.36%
Market Cap83.75B
Revenue(TTM)14.34B
Net Income(TTM)4.50B
Analysts81.11
Price Target862.4 (8.87%)
Short Float %2.14%
Short Ratio2.47
Dividend
Industry RankSector Rank
Dividend Yield 0.48%
Yearly Dividend3.44
Dividend Growth(5Y)N/A
DP8.22%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.31%
Min EPS beat(2)5.66%
Max EPS beat(2)20.96%
EPS beat(4)3
Avg EPS beat(4)16.93%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.59%
EPS beat(12)10
Avg EPS beat(12)8.05%
EPS beat(16)13
Avg EPS beat(16)8.3%
Revenue beat(2)2
Avg Revenue beat(2)1.44%
Min Revenue beat(2)0.21%
Max Revenue beat(2)2.66%
Revenue beat(4)3
Avg Revenue beat(4)0.82%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.06%
Revenue beat(12)8
Avg Revenue beat(12)0.91%
Revenue beat(16)12
Avg Revenue beat(16)1.57%
PT rev (1m)6.7%
PT rev (3m)15.32%
EPS NQ rev (1m)-12.92%
EPS NQ rev (3m)-10.94%
EPS NY rev (1m)0.85%
EPS NY rev (3m)4.59%
Revenue NQ rev (1m)-0.45%
Revenue NQ rev (3m)0.74%
Revenue NY rev (1m)2.24%
Revenue NY rev (3m)4.54%
Valuation
Industry RankSector Rank
PE 17.85
Fwd PE 17.05
P/S 5.84
P/FCF 22.24
P/OCF 16.82
P/B 2.68
P/tB 2.79
EV/EBITDA 12.85
EPS(TTM)44.38
EY5.6%
EPS(NY)46.46
Fwd EY5.86%
FCF(TTM)35.61
FCFY4.5%
OCF(TTM)47.1
OCFY5.95%
SpS135.67
BVpS295.66
TBVpS283.76
PEG (NY)3.82
PEG (5Y)2.55
Graham Number543.35
Profitability
Industry RankSector Rank
ROA 11.11%
ROE 14.41%
ROCE 10.71%
ROIC 9.6%
ROICexc 29.34%
ROICexgc 32.83%
OM 27.02%
PM (TTM) 31.41%
GM 86.56%
FCFM 26.25%
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)11.3%
ROIC(5y)18.08%
ROICexc(3y)21.75%
ROICexc(5y)28.65%
ROICexgc(3y)23.56%
ROICexgc(5y)30%
ROCE(3y)12.6%
ROCE(5y)20.17%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y2.24%
ROICexc growth 3Y4.54%
ROICexc growth 5Y-0.03%
OM growth 3Y-14.45%
OM growth 5Y-8.44%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.04%
GM growth 5Y-0.06%
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.72
Debt/EBITDA 0.61
Cap/Depr 223.23%
Cap/Sales 8.46%
Interest Coverage 93.15
Cash Conversion 112.68%
Profit Quality 83.58%
Current Ratio 4.13
Quick Ratio 3.56
Altman-Z 7.72
F-Score5
WACC8.46%
ROIC/WACC1.13
Cap/Depr(3y)208.61%
Cap/Depr(5y)258.46%
Cap/Sales(3y)7.24%
Cap/Sales(5y)7.69%
Profit Quality(3y)85.52%
Profit Quality(5y)83.15%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
EPS Next Y4.68%
EPS Next 2Y11.02%
EPS Next 3Y11.23%
EPS Next 5Y11%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%
Revenue Next Year9.08%
Revenue Next 2Y9.41%
Revenue Next 3Y8.95%
Revenue Next 5Y8.09%
EBIT growth 1Y-8.13%
EBIT growth 3Y-9.64%
EBIT growth 5Y1.67%
EBIT Next Year12.49%
EBIT Next 3Y19.46%
EBIT Next 5Y10.58%
FCF growth 1Y6.39%
FCF growth 3Y3.48%
FCF growth 5Y13.45%
OCF growth 1Y12.63%
OCF growth 3Y-0.24%
OCF growth 5Y13.72%

REGENERON PHARMACEUTICALS / REGN FAQ

Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?

ChartMill assigns a fundamental rating of 6 / 10 to REGN.


What is the valuation status of REGENERON PHARMACEUTICALS (REGN) stock?

ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.


Can you provide the profitability details for REGENERON PHARMACEUTICALS?

REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 7 / 10.


What is the financial health of REGENERON PHARMACEUTICALS (REGN) stock?

The financial health rating of REGENERON PHARMACEUTICALS (REGN) is 8 / 10.


How sustainable is the dividend of REGENERON PHARMACEUTICALS (REGN) stock?

The dividend rating of REGENERON PHARMACEUTICALS (REGN) is 3 / 10 and the dividend payout ratio is 8.22%.